Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study-MedSci.cn

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Jaeger, U; Egle, A; Simonitsch-Klupp, I; Heibl, S; Neumeister, P; Willenbacher, E; Erlsbacher, F; Larcher-Senn, J; Fridrik, MA; Greil, R

BLOOD, 2020; 136 ():

科室
- - 订阅+
  - 更多科室
工具
服务